Articles

Find an Article

Filter articles

Applied Filters

Showing 211 to 220 of 272 results

Patent protection for microorganisms

EU04-11-2014Peter ten Haaft

Depositing a microorganism in a country may be crucial for obtaining a method patent in that jurisdiction, but can come with its pitfalls, says Peter ten Haaft.

Patenting Parthenotes

EU04-11-2014Franz-Josef Zimmer and Markus Grammel

Earlier this year, the Advocate General of 
the CJEU opined that stem cells from parthenotes are patentable. Franz-Josef Zimmer and Markus Grammel examine the reasoning behind his opinion.

The Nagoya Protocol and what it means for the EU

EU, Japan03-11-2014Richard Bassett and Richard Wells

Richard Bassett and Richard Wells look at what EU-based companies must consider in order to comply with the Nagoya Protocol, the regulation aimed at curbing biopiracy.

The perils of clinical trials: confidentiality and infringement

EU, UK03-11-2014Dennis Waller

Dennis Waller discusses how differing interpretations of the Bolar exemption may affect clinical trials in the UK.

Insurance 
companies v AstraZeneca

UK, US03-11-2014Jason Rutt

Jason Rutt considers the impact AstraZeneca’s recent US pay-for-delay case will have on the industry.

A bright future for AstraZeneca?

Sweden, UK, US03-11-2014

AstraZeneca has had a tough few years, with a clutch of patent expiries one of the most serious of its problems. So where does it go from here? To find out, LSIPR spoke to the Anglo-Swedish pharmaceutical company’s vice president of business development about the role IP is playing in its plans for future success.

HGS: where are we now with SPCs?

EU29-10-2014Ashley Roughton

Should it be possible for a drug maker to stop the owner of a patented ingredient from obtaining an SPC? Ashley Roughton examines the CJEU’s opinion on Eli Lilly v HGS.

LSIPR roundtable

UK, US30-09-2014

Earlier this month, the first LSIPR roundtable discussion took place in a London hotel, chaired by managing editor Martin Essex, with six invited experts and deputy editor 
Ed Conlon taking part. We’ll be publishing a special report on the event but, to whet your appetite, here’s how the discussion began—with a lively debate on the USPTO’s guidelines on patent-eligible subject matter in the wake of the Myriad and Mayo court decisions.

Patenting stem cells: filing date is the key

EU07-07-2014Joachim Wachenfeld

The EPO generally accepts applications relating to human embryonic stem cells with an effective date after 2008 but discussions about eligibility continue, says Joachim Wachenfeld.

Not just for medicaments: broadening horizons in Europe

EU20-06-2014Andrew Wright and Tom Harding

Andrew Wright and Tom Harding investigate how a decision by the EPO’s Board of Appeal may extend the opportunities for protection by second medical use claims.

Showing 211 to 220 of 272 results

LSIPR